Literature DB >> 30171665

Aggressive prevention and preemptive management of vascular complications after pediatric liver transplantation: A major impact on graft survival and long-term outcome.

Chiara Grimaldi1, Fabrizio di Francesco2, Fabrizio Chiusolo3, Roberta Angelico1, Lidia Monti3, Paolo Muiesan4, Jean de Ville de Goyet2.   

Abstract

Vascular complications are a major cause of patient and graft loss after LTs. The aim of this study was to evaluate the effect of a multimodal perioperative strategy aimed at reducing the incidence of vascular complications. A total of 126 first isolated LTs-performed between November 2008 and December 2015-were retrospectively analyzed. A minimum follow-up period of 24 months was analyzable for 124/126 patients (98.4%). The aggressive preemptive strategy consisted of identifying and immediately managing any problem and any abnormality in the vascular flow, in any of the hepatic vessels, and at any time after the liver graft revascularization. As a result, with a median follow-up of 57 months (3-112 months), not a single graft has been lost from vascular or biliary problems. The actuarial 8-year graft survival is 96.5%. These results have shown that a combination of technical attention, medical prevention, an early diagnosis, and rapid interventions reduced the negative impact of vascular problems on the outcome of both grafts and patients.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  children; liver transplantation; outcome; techniques; vascular complications

Mesh:

Year:  2018        PMID: 30171665     DOI: 10.1111/petr.13288

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  1 in total

1.  Therapeutic Drug Monitoring of Amphotericin-B in Plasma and Peritoneal Fluid of Pediatric Patients after Liver Transplantation: A Case Series.

Authors:  Francesca Tortora; Luigi Dei Giudici; Raffaele Simeoli; Fabrizio Chiusolo; Sara Cairoli; Paola Bernaschi; Roberto Bianchi; Sergio Giuseppe Picardo; Carlo Dionisi Vici; Bianca Maria Goffredo
Journal:  Antibiotics (Basel)       Date:  2022-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.